AN2 Therapeutics 2026 shareholder voting results

AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders.

(Moderate)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. reported the results of its 2026 annual meeting of stockholders. A quorum was present, with 22,741,535 shares represented, equal to 63.18% of the 35,995,545 shares outstanding as of April 15, 2026.

Stockholders elected Class I directors Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., to serve until the 2029 annual meeting or until their successors are chosen. Support ranged from 13,547,536 to 15,947,854 votes for, with broker non-votes of 5,235,125 on each nominee.

Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 22,724,674 votes for, 13 votes against, and 16,848 abstentions.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares represented: 22,741,535 shares Shares outstanding: 35,995,545 shares Quorum percentage: 63.18% +4 more

7 metrics

Shares represented 22,741,535 shares Present at 2026 annual meeting

Shares outstanding 35,995,545 shares Common stock outstanding as of April 15, 2026

Quorum percentage 63.18% Portion of outstanding shares represented at meeting

Votes for Aziz 13,547,536 votes Election of director Kabeer Aziz

Votes for Marks 15,947,854 votes Election of director Gilbert Lynn Marks, M.D.

Votes for Readnour 15,920,563 votes Election of director Rob Readnour, Ph.D.

Auditor ratification for votes 22,724,674 votes Ratification of PricewaterhouseCoopers LLP

Key Terms

broker non-votes, independent registered public accounting firm, emerging growth company, record date

4 terms

broker non-votes financial

"including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

emerging growth company regulatory

"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

record date financial

"outstanding as of the close of business on April 15, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did AN2 Therapeutics (ANTX) report from its 2026 annual meeting?

AN2 Therapeutics reported the voting results from its 2026 annual meeting. Shareholders elected three Class I directors and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

How many AN2 Therapeutics (ANTX) shares were represented at the 2026 meeting?

A total of 22,741,535 AN2 Therapeutics common shares were represented in person or by proxy. This equaled 63.18% of the 35,995,545 shares outstanding as of April 15, 2026, which satisfied quorum requirements for conducting business.

Which directors were elected at the AN2 Therapeutics (ANTX) 2026 annual meeting?

Stockholders elected Kabeer Aziz, Gilbert Lynn Marks, M.D., and Rob Readnour, Ph.D., as Class I directors. They will serve until the 2029 annual meeting of stockholders or until their respective successors are elected or appointed, according to the reported vote results.

What were the vote totals for AN2 Therapeutics (ANTX) auditor ratification?

Shareholders ratified PricewaterhouseCoopers LLP as AN2 Therapeutics’ independent registered public accounting firm. The proposal received 22,724,674 votes for, 13 votes against, and 16,848 abstentions for the fiscal year ending December 31, 2026.

What was the record date for AN2 Therapeutics (ANTX) 2026 annual meeting voting eligibility?

The record date for determining shareholders entitled to vote at AN2 Therapeutics’ 2026 annual meeting was April 15, 2026. On that date, 35,995,545 shares of common stock were outstanding and eligible to be counted for quorum and voting purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 06:23 PM EDT

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): June 03, 2026

    

AN2 Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41331	82-0606654
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1300 El Camino Real, Suite 100
Menlo Park, California		94025
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 650 331-9090

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	ANTX	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 3, 2026, AN2 Therapeutics, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting in person or via proxy were the holders of 22,741,535 shares of common stock of the Company, representing 63.18% of the 35,995,545 shares of common stock outstanding as of the close of business on April 15, 2026, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.

At the Annual Meeting, the Company’s stockholders voted on two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 22, 2026. The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each matter.

To elect the nominees Kabeer Aziz, Gilbert Lynn Marks, M.D. and Rob Readnour, Ph.D. as Class I directors until the Company’s 2029 annual meeting of stockholders or until their respective successors have been elected or appointed. The voting results were as follows:


Name	Votes For	Votes Withheld	Broker Non-Votes
Kabeer Aziz	13,547,536	3,958,874	5,235,125
Gilbert Lynn Marks, M.D.	15,947,854	1,558,556	5,235,125
Rob Readnour, Ph.D.	15,920,563	1,585,847	5,235,125

To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows:


Votes For	Votes Against	Abstentions
22,724,674	13	16,848

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			AN2 Therapeutics, Inc.

Date:	June 8, 2026	By:	/s/ Joshua Eizen
			Joshua Eizen Chief Legal Officer and Chief Operating Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document